Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q1

9987.TEDINET S100OZ8T
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥553.8bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥541.1bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥3.5bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income−¥1.6bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥4.6bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥443m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥4.5bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax−¥479m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥2.7bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥414m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥2.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income−¥373m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥1.17Tat 2022-06-30Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.17Tat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥745.8bnat 2022-06-30Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥419.3bnat 2022-06-30Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥415.3bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥132.1bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥30.492022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.662021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio36.0%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.4%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥52.6bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥42.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥434m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥21.4bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥21.4bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥31m
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥533.5bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥519.6bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥13.8bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.5bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥8.6bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥587m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥618.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥553.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥65.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥41.9bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥9.8bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥32.1bn
jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥644m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥21.9bn
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5m
jpcrp040300-q1r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥323m
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥520.1bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥506.1bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥13.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥3.2bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥11.3bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥3.3bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥7.9bn
jpcrp040300-q1r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥468m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥595.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥541.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥54.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30−¥1.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 350
ItemContextValueUnit
Operating incomeCurrentYTDDuration3550000000JPY
Interest income noiPrior1YTDDuration32000000JPY
Interest income noiCurrentYTDDuration28000000JPY
Dividends income noiPrior1YTDDuration704000000JPY
Dividends income noiCurrentYTDDuration478000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration128000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration294000000JPY
Other noiPrior1YTDDuration451000000JPY
Other noiCurrentYTDDuration327000000JPY
Non operating incomePrior1YTDDuration1316000000JPY
Non operating incomeCurrentYTDDuration1129000000JPY
Interest expenses noePrior1YTDDuration17000000JPY
Interest expenses noeCurrentYTDDuration11000000JPY
Rent expenses on real estates noePrior1YTDDuration58000000JPY
Rent expenses on real estates noeCurrentYTDDuration53000000JPY
Other noePrior1YTDDuration47000000JPY
Other noeCurrentYTDDuration56000000JPY
Non operating expensesPrior1YTDDuration124000000JPY
Non operating expensesCurrentYTDDuration121000000JPY
Ordinary incomePrior1YTDDuration-443000000JPY
Ordinary incomeCurrentYTDDuration4558000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration5000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration0JPY
Gain on transfer of business eiPrior1YTDDuration－JPY
Gain on transfer of business eiCurrentYTDDuration21000000JPY
Other eiPrior1YTDDuration0JPY
Other eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration6000000JPY
Extraordinary incomeCurrentYTDDuration21000000JPY
Loss on sales and retirement of noncurrent assets elPrior1YTDDuration18000000JPY
Loss on sales and retirement of noncurrent assets elCurrentYTDDuration27000000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration20000000JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration－JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration77000000JPY
Other elPrior1YTDDuration3000000JPY
Other elCurrentYTDDuration1000000JPY
Extraordinary lossPrior1YTDDuration42000000JPY
Extraordinary lossCurrentYTDDuration106000000JPY
Income before income taxesPrior1YTDDuration-479000000JPY
Income before income taxesCurrentYTDDuration4473000000JPY
Income taxesPrior1YTDDuration-106000000JPY
Income taxesCurrentYTDDuration1798000000JPY
Profit lossPrior1YTDDuration-373000000JPY
Profit lossCurrentYTDDuration2674000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration41000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-6000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-414000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration2681000000JPY
Profit lossPrior1YTDDuration-373000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass